Lipella reports positive phase 2a results from second lp-310 cohort in oral lichen planus; final data expected q2 2025

Second cohort results highlight efficacy across all key measures and reinforce safety of twice-daily oral rinse phase 2a study now fully enrolled across all three dose cohorts advancing toward phase 2b ind submission and broader regulatory engagement pittsburgh, april 22, 2025 (globe newswire) -- lipella pharmaceuticals inc. (nasdaq: lipo) (“lipella,” “our,” “us,” or the “company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today announced positive topline results from the second cohort (0.50 mg) of its phase 2a multicenter, dose-ranging trial evaluating lp-310, a liposomal-tacrolimus oral rinse formulation of lp-10, for the treatment of oral lichen planus (olp). the company also recently reported full enrollment across all three planned dose cohorts.
LIPO Ratings Summary
LIPO Quant Ranking